Hundreds of British drugmaker GlaxoSmithKline’s 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry’s latest restructuring.
Hundreds of British drugmaker GlaxoSmithKline’s 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry’s latest restructuring.